Does the media prefer IMVT or RXRX?

In the previous week, Recursion Pharmaceuticals had 9 more articles in the media than Immunovant. MarketBeat recorded 13 mentions for Recursion Pharmaceuticals and 4 mentions for Immunovant. Recursion Pharmaceuticals' average media sentiment score of 0.61 beat Immunovant's score of 0.41 indicating that Recursion Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Immunovant 2 Very Positive mention(s) 2 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Recursion Pharmaceuticals 5 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Positive

Does the media favor RXRX or KYMR?

In the previous week, Recursion Pharmaceuticals had 11 more articles in the media than Kymera Therapeutics. MarketBeat recorded 13 mentions for Recursion Pharmaceuticals and 2 mentions for Kymera Therapeutics. Kymera Therapeutics' average media sentiment score of 1.05 beat Recursion Pharmaceuticals' score of 0.61 indicating that Kymera Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Recursion Pharmaceuticals 5 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Positive Kymera Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer LNTH or RXRX?

In the previous week, Recursion Pharmaceuticals had 9 more articles in the media than Lantheus. MarketBeat recorded 13 mentions for Recursion Pharmaceuticals and 4 mentions for Lantheus. Recursion Pharmaceuticals' average media sentiment score of 0.61 beat Lantheus' score of 0.20 indicating that Recursion Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Lantheus 1 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Recursion Pharmaceuticals 5 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Positive

Does the media refer more to RXRX or RYTM?

In the previous week, Recursion Pharmaceuticals had 11 more articles in the media than Rhythm Pharmaceuticals. MarketBeat recorded 13 mentions for Recursion Pharmaceuticals and 2 mentions for Rhythm Pharmaceuticals. Recursion Pharmaceuticals' average media sentiment score of 0.61 beat Rhythm Pharmaceuticals' score of 0.60 indicating that Recursion Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Recursion Pharmaceuticals 5 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Positive Rhythm Pharmaceuticals 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Recursion Pharmaceuticals (RXRX) Competitors

$3.32 -0.48 (-12.63%)

Closing price 04:00 PM Eastern

Extended Trading

$3.29 -0.03 (-0.78%)

As of 07:59 PM Eastern

Compare

RXRX vs. IMVT, KYMR, LNTH, PTGX, and RYTM

Should you buy Recursion Pharmaceuticals stock or one of its competitors? MarketBeat compares Recursion Pharmaceuticals with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Recursion Pharmaceuticals include Immunovant (IMVT), Kymera Therapeutics (KYMR), Lantheus (LNTH), Protagonist Therapeutics (PTGX), and Rhythm Pharmaceuticals (RYTM). These companies are all part of the "pharmaceutical products" industry.

How does Recursion Pharmaceuticals compare to Immunovant?

Immunovant (NASDAQ:IMVT) and Recursion Pharmaceuticals (NASDAQ:RXRX) are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their dividends, media sentiment, institutional ownership, analyst recommendations, profitability, valuation, earnings and risk.

Immunovant has a net margin of 0.00% compared to Recursion Pharmaceuticals' net margin of -842.95%. Recursion Pharmaceuticals' return on equity of -54.33% beat Immunovant's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Immunovant	N/A	-65.66%	-59.88%
Recursion Pharmaceuticals	-842.95%	-54.33%	-40.60%

Immunovant currently has a consensus target price of $37.33, suggesting a potential upside of 20.00%. Recursion Pharmaceuticals has a consensus target price of $8.10, suggesting a potential upside of 143.98%. Given Recursion Pharmaceuticals' higher possible upside, analysts plainly believe Recursion Pharmaceuticals is more favorable than Immunovant.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Immunovant	1 Sell rating(s)	4 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.45
Recursion Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.20

47.1% of Immunovant shares are held by institutional investors. Comparatively, 89.1% of Recursion Pharmaceuticals shares are held by institutional investors. 1.8% of Immunovant shares are held by company insiders. Comparatively, 8.4% of Recursion Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Immunovant has higher earnings, but lower revenue than Recursion Pharmaceuticals. Immunovant is trading at a lower price-to-earnings ratio than Recursion Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Immunovant	N/A	N/A	-$505.61M	-$2.78	N/A
Recursion Pharmaceuticals	$65.74M	26.76	-$644.76M	-$1.20	N/A

In the previous week, Recursion Pharmaceuticals had 9 more articles in the media than Immunovant. MarketBeat recorded 13 mentions for Recursion Pharmaceuticals and 4 mentions for Immunovant. Recursion Pharmaceuticals' average media sentiment score of 0.61 beat Immunovant's score of 0.41 indicating that Recursion Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Immunovant	2 Very Positive mention(s)	2 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Recursion Pharmaceuticals	5 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Positive

Immunovant has a beta of 0.76, meaning that its stock price is 24% less volatile than the broader market. Comparatively, Recursion Pharmaceuticals has a beta of 1.04, meaning that its stock price is 4% more volatile than the broader market.

Summary

Recursion Pharmaceuticals beats Immunovant on 11 of the 15 factors compared between the two stocks.

How does Recursion Pharmaceuticals compare to Kymera Therapeutics?

Recursion Pharmaceuticals (NASDAQ:RXRX) and Kymera Therapeutics (NASDAQ:KYMR) are both medical companies, but which is the superior business? We will compare the two companies based on the strength of their media sentiment, analyst recommendations, risk, profitability, dividends, valuation, institutional ownership and earnings.

Kymera Therapeutics has a net margin of -611.94% compared to Recursion Pharmaceuticals' net margin of -842.95%. Kymera Therapeutics' return on equity of -24.71% beat Recursion Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Recursion Pharmaceuticals	-842.95%	-54.33%	-40.60%
Kymera Therapeutics	-611.94%	-24.71%	-22.05%

Kymera Therapeutics has lower revenue, but higher earnings than Recursion Pharmaceuticals. Kymera Therapeutics is trading at a lower price-to-earnings ratio than Recursion Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Recursion Pharmaceuticals	$65.74M	26.76	-$644.76M	-$1.20	N/A
Kymera Therapeutics	$51.48M	118.46	-$311.35M	-$3.57	N/A

Recursion Pharmaceuticals has a beta of 1.04, indicating that its stock price is 4% more volatile than the broader market. Comparatively, Kymera Therapeutics has a beta of 2.02, indicating that its stock price is 102% more volatile than the broader market.

In the previous week, Recursion Pharmaceuticals had 11 more articles in the media than Kymera Therapeutics. MarketBeat recorded 13 mentions for Recursion Pharmaceuticals and 2 mentions for Kymera Therapeutics. Kymera Therapeutics' average media sentiment score of 1.05 beat Recursion Pharmaceuticals' score of 0.61 indicating that Kymera Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Recursion Pharmaceuticals	5 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Positive
Kymera Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

89.1% of Recursion Pharmaceuticals shares are owned by institutional investors. 8.4% of Recursion Pharmaceuticals shares are owned by insiders. Comparatively, 16.0% of Kymera Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Recursion Pharmaceuticals presently has a consensus target price of $8.10, suggesting a potential upside of 143.98%. Kymera Therapeutics has a consensus target price of $118.10, suggesting a potential upside of 59.31%. Given Recursion Pharmaceuticals' higher possible upside, equities research analysts plainly believe Recursion Pharmaceuticals is more favorable than Kymera Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Recursion Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.20
Kymera Therapeutics	1 Sell rating(s)	0 Hold rating(s)	20 Buy rating(s)	1 Strong Buy rating(s)	2.95

Summary

Kymera Therapeutics beats Recursion Pharmaceuticals on 11 of the 17 factors compared between the two stocks.

How does Recursion Pharmaceuticals compare to Lantheus?

Lantheus (NASDAQ:LNTH) and Recursion Pharmaceuticals (NASDAQ:RXRX) are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their valuation, earnings, dividends, risk, profitability, media sentiment, analyst recommendations and institutional ownership.

Lantheus has a beta of -0.03, indicating that its stock price is 103% less volatile than the broader market. Comparatively, Recursion Pharmaceuticals has a beta of 1.04, indicating that its stock price is 4% more volatile than the broader market.

In the previous week, Recursion Pharmaceuticals had 9 more articles in the media than Lantheus. MarketBeat recorded 13 mentions for Recursion Pharmaceuticals and 4 mentions for Lantheus. Recursion Pharmaceuticals' average media sentiment score of 0.61 beat Lantheus' score of 0.20 indicating that Recursion Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Lantheus	1 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Recursion Pharmaceuticals	5 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Positive

Lantheus presently has a consensus price target of $101.86, indicating a potential upside of 0.87%. Recursion Pharmaceuticals has a consensus price target of $8.10, indicating a potential upside of 143.98%. Given Recursion Pharmaceuticals' higher probable upside, analysts clearly believe Recursion Pharmaceuticals is more favorable than Lantheus.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Lantheus	0 Sell rating(s)	3 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.73
Recursion Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.20

99.1% of Lantheus shares are owned by institutional investors. Comparatively, 89.1% of Recursion Pharmaceuticals shares are owned by institutional investors. 1.7% of Lantheus shares are owned by insiders. Comparatively, 8.4% of Recursion Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Lantheus has a net margin of 18.05% compared to Recursion Pharmaceuticals' net margin of -842.95%. Lantheus' return on equity of 29.32% beat Recursion Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Lantheus	18.05%	29.32%	15.00%
Recursion Pharmaceuticals	-842.95%	-54.33%	-40.60%

Lantheus has higher revenue and earnings than Recursion Pharmaceuticals. Recursion Pharmaceuticals is trading at a lower price-to-earnings ratio than Lantheus, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Lantheus	$1.55B	4.25	$233.56M	$4.15	24.33
Recursion Pharmaceuticals	$65.74M	26.76	-$644.76M	-$1.20	N/A

Summary

Lantheus beats Recursion Pharmaceuticals on 10 of the 16 factors compared between the two stocks.

How does Recursion Pharmaceuticals compare to Protagonist Therapeutics?

Protagonist Therapeutics (NASDAQ:PTGX) and Recursion Pharmaceuticals (NASDAQ:RXRX) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their risk, analyst recommendations, institutional ownership, earnings, valuation, dividends, profitability and media sentiment.

In the previous week, Recursion Pharmaceuticals had 6 more articles in the media than Protagonist Therapeutics. MarketBeat recorded 13 mentions for Recursion Pharmaceuticals and 7 mentions for Protagonist Therapeutics. Protagonist Therapeutics' average media sentiment score of 0.78 beat Recursion Pharmaceuticals' score of 0.61 indicating that Protagonist Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Protagonist Therapeutics	4 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Recursion Pharmaceuticals	5 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Positive

Protagonist Therapeutics has higher revenue and earnings than Recursion Pharmaceuticals. Protagonist Therapeutics is trading at a lower price-to-earnings ratio than Recursion Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Protagonist Therapeutics	$74.06M	84.56	-$130.15M	-$1.81	N/A
Recursion Pharmaceuticals	$65.74M	26.76	-$644.76M	-$1.20	N/A

Protagonist Therapeutics has a net margin of -154.88% compared to Recursion Pharmaceuticals' net margin of -842.95%. Protagonist Therapeutics' return on equity of -17.76% beat Recursion Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Protagonist Therapeutics	-154.88%	-17.76%	-16.47%
Recursion Pharmaceuticals	-842.95%	-54.33%	-40.60%

Protagonist Therapeutics has a beta of 1.85, indicating that its share price is 85% more volatile than the broader market. Comparatively, Recursion Pharmaceuticals has a beta of 1.04, indicating that its share price is 4% more volatile than the broader market.

98.6% of Protagonist Therapeutics shares are held by institutional investors. Comparatively, 89.1% of Recursion Pharmaceuticals shares are held by institutional investors. 5.2% of Protagonist Therapeutics shares are held by company insiders. Comparatively, 8.4% of Recursion Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Protagonist Therapeutics presently has a consensus price target of $115.21, suggesting a potential upside of 18.31%. Recursion Pharmaceuticals has a consensus price target of $8.10, suggesting a potential upside of 143.98%. Given Recursion Pharmaceuticals' higher probable upside, analysts clearly believe Recursion Pharmaceuticals is more favorable than Protagonist Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Protagonist Therapeutics	1 Sell rating(s)	1 Hold rating(s)	13 Buy rating(s)	1 Strong Buy rating(s)	2.88
Recursion Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.20

Summary

Protagonist Therapeutics beats Recursion Pharmaceuticals on 12 of the 17 factors compared between the two stocks.

How does Recursion Pharmaceuticals compare to Rhythm Pharmaceuticals?

Recursion Pharmaceuticals (NASDAQ:RXRX) and Rhythm Pharmaceuticals (NASDAQ:RYTM) are both medical companies, but which is the superior investment? We will compare the two companies based on the strength of their analyst recommendations, dividends, valuation, earnings, profitability, risk, institutional ownership and media sentiment.

In the previous week, Recursion Pharmaceuticals had 11 more articles in the media than Rhythm Pharmaceuticals. MarketBeat recorded 13 mentions for Recursion Pharmaceuticals and 2 mentions for Rhythm Pharmaceuticals. Recursion Pharmaceuticals' average media sentiment score of 0.61 beat Rhythm Pharmaceuticals' score of 0.60 indicating that Recursion Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Recursion Pharmaceuticals	5 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Positive
Rhythm Pharmaceuticals	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Rhythm Pharmaceuticals has higher revenue and earnings than Recursion Pharmaceuticals. Rhythm Pharmaceuticals is trading at a lower price-to-earnings ratio than Recursion Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Recursion Pharmaceuticals	$65.74M	26.76	-$644.76M	-$1.20	N/A
Rhythm Pharmaceuticals	$217.17M	27.27	-$196.54M	-$3.13	N/A

Rhythm Pharmaceuticals has a net margin of -93.33% compared to Recursion Pharmaceuticals' net margin of -842.95%. Recursion Pharmaceuticals' return on equity of -54.33% beat Rhythm Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Recursion Pharmaceuticals	-842.95%	-54.33%	-40.60%
Rhythm Pharmaceuticals	-93.33%	-203.25%	-44.99%

Recursion Pharmaceuticals has a beta of 1.04, meaning that its stock price is 4% more volatile than the broader market. Comparatively, Rhythm Pharmaceuticals has a beta of 1.91, meaning that its stock price is 91% more volatile than the broader market.

89.1% of Recursion Pharmaceuticals shares are owned by institutional investors. 8.4% of Recursion Pharmaceuticals shares are owned by insiders. Comparatively, 5.9% of Rhythm Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Recursion Pharmaceuticals presently has a consensus target price of $8.10, suggesting a potential upside of 143.98%. Rhythm Pharmaceuticals has a consensus target price of $131.81, suggesting a potential upside of 52.56%. Given Recursion Pharmaceuticals' higher probable upside, analysts plainly believe Recursion Pharmaceuticals is more favorable than Rhythm Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Recursion Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.20
Rhythm Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	14 Buy rating(s)	1 Strong Buy rating(s)	2.83

Summary

Recursion Pharmaceuticals beats Rhythm Pharmaceuticals on 9 of the 17 factors compared between the two stocks.

Get Recursion Pharmaceuticals News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding RXRX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

RXRX vs. The Competition

Export

Metric	Recursion Pharmaceuticals	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$1.76B	$2.93B	$6.44B	$11.97B
Dividend Yield	N/A	1.69%	2.69%	5.32%
P/E Ratio	-2.77	17.86	23.77	23.66
Price / Sales	26.76	293.66	488.50	86.29
Price / Cash	N/A	55.54	41.39	55.53
Price / Book	1.55	3.83	9.76	6.39
Net Income	-$644.76M	$75.85M	$3.56B	$337.36M
7 Day Performance	-7.52%	-4.88%	-3.19%	-3.07%
1 Month Performance	-1.48%	-5.87%	-0.11%	0.37%
1 Year Performance	-27.35%	18.98%	25.29%	27.87%

Recursion Pharmaceuticals Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
RXRX Recursion Pharmaceuticals	2.6706 of 5 stars	$3.32 -12.6%	$8.10 +144.0%	-22.6%	$1.76B	$65.74M	N/A	400	Trending News Insider Trade Gap Down
IMVT Immunovant	2.2243 of 5 stars	$33.30 -0.6%	$37.33 +12.1%	+113.0%	$6.88B	N/A	N/A	120
KYMR Kymera Therapeutics	2.1635 of 5 stars	$81.42 0.0%	$118.10 +45.0%	+68.6%	$6.70B	$39.21M	N/A	170	Gap Up
LNTH Lantheus	2.0205 of 5 stars	$99.30 -0.3%	$101.86 +2.6%	+29.1%	$6.49B	$1.54B	23.93	1,193
PTGX Protagonist Therapeutics	2.5731 of 5 stars	$99.56 -0.8%	$115.21 +15.7%	+99.5%	$6.46B	$74.06M	N/A	120	Gap Up

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:RXRX) was last updated on 6/5/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Recursion Pharmaceuticals (RXRX) Competitors

RXRX vs. IMVT, KYMR, LNTH, PTGX, and RYTM

How does Recursion Pharmaceuticals compare to Immunovant?

Summary

How does Recursion Pharmaceuticals compare to Kymera Therapeutics?

Summary

How does Recursion Pharmaceuticals compare to Lantheus?

Summary

How does Recursion Pharmaceuticals compare to Protagonist Therapeutics?

Summary

How does Recursion Pharmaceuticals compare to Rhythm Pharmaceuticals?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

RXRX vs. The Competition

Recursion Pharmaceuticals Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Recursion Pharmaceuticals (RXRX) Competitors

RXRX vs. IMVT, KYMR, LNTH, PTGX, and RYTM

How does Recursion Pharmaceuticals compare to Immunovant?

Is IMVT or RXRX more profitable?

Do analysts rate IMVT or RXRX?

Do institutionals & insiders believe in IMVT or RXRX?

Which has stronger earnings and valuation, IMVT or RXRX?

Does the media prefer IMVT or RXRX?

Which has more volatility and risk, IMVT or RXRX?

Summary

How does Recursion Pharmaceuticals compare to Kymera Therapeutics?

Is RXRX or KYMR more profitable?

Which has preferable earnings and valuation, RXRX or KYMR?

Which has more volatility & risk, RXRX or KYMR?

Does the media favor RXRX or KYMR?

Do institutionals and insiders hold more shares of RXRX or KYMR?

Do analysts rate RXRX or KYMR?

Summary

How does Recursion Pharmaceuticals compare to Lantheus?

Which has more risk & volatility, LNTH or RXRX?

Does the media prefer LNTH or RXRX?

Do analysts prefer LNTH or RXRX?

Do institutionals & insiders have more ownership in LNTH or RXRX?

Is LNTH or RXRX more profitable?

Which has higher earnings & valuation, LNTH or RXRX?

Summary

How does Recursion Pharmaceuticals compare to Protagonist Therapeutics?

Does the media prefer PTGX or RXRX?

Which has preferable earnings & valuation, PTGX or RXRX?

Is PTGX or RXRX more profitable?

Which has more risk and volatility, PTGX or RXRX?

Do insiders and institutionals believe in PTGX or RXRX?

Do analysts prefer PTGX or RXRX?

Summary

How does Recursion Pharmaceuticals compare to Rhythm Pharmaceuticals?

Does the media refer more to RXRX or RYTM?

Which has preferable valuation & earnings, RXRX or RYTM?

Is RXRX or RYTM more profitable?

Which has more risk & volatility, RXRX or RYTM?

Do institutionals & insiders hold more shares of RXRX or RYTM?

Do analysts prefer RXRX or RYTM?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

RXRX vs. The Competition

Recursion Pharmaceuticals Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools